BioMarin's Record Q1 Driven by Recently Approved Achondroplasia Therapy

In November, BioMarin’s Voxzogo (vosoritide) became the first U.S. Food and Drug Administration-approved therapy for children with achondroplasia, a rare genetic disorder that causes the most common form of dwarfism. The drug has already made a sizeable contribution, adding nearly $20 million to BioMarin’s best first quarter to date.